D W Steyn1, P Steyn. 1. University of Stellenbosch, Department of Obstetrics & Gynaecology, PO Box 19063, Tygerberg, Stellenbosch, South Africa, 7505. dws@sun.ac.za
Abstract
BACKGROUND: Hypertensive disorders during pregnancy are important causes of maternal mortality and morbidity worldwide. The long-term outcome of surviving mothers will depend largely on whether intracranial haemorrhage or renal failure developed. Low-dose dopamine is used for the prevention and treatment of acute renal failure, but its role in the management of pregnant women with severe pre-eclampsia is unclear. OBJECTIVES: To assess the effects of low-dose dopamine used for oliguria in severe pre-eclampsia on mothers and their children. SEARCH STRATEGY: We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (June 2006). SELECTION CRITERIA: Randomised trials comparing low-dose dopamine (dosages not higher than 5 microgram/kg/minute) with either placebo or no dopamine in women with severe pre-eclampsia and acute renal failure, or who are considered to be at risk of acute renal failure. DATA COLLECTION AND ANALYSIS: The two review authors assessed trial quality and data independently. MAIN RESULTS: Only one randomised placebo controlled trial of six hours' duration, including 40 postpartum women, was found. This study showed a significant increase in urinary output over six hours in women receiving dopamine. It is unclear if this was of any benefit to the women. AUTHORS' CONCLUSIONS: It is unclear whether low-dose dopamine therapy for pre-eclamptic women with oliguria is worthwhile. It should not be used other than in prospective trials.
BACKGROUND: Hypertensive disorders during pregnancy are important causes of maternal mortality and morbidity worldwide. The long-term outcome of surviving mothers will depend largely on whether intracranial haemorrhage or renal failure developed. Low-dose dopamine is used for the prevention and treatment of acute renal failure, but its role in the management of pregnant women with severe pre-eclampsia is unclear. OBJECTIVES: To assess the effects of low-dose dopamine used for oliguria in severe pre-eclampsia on mothers and their children. SEARCH STRATEGY: We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (June 2006). SELECTION CRITERIA: Randomised trials comparing low-dose dopamine (dosages not higher than 5 microgram/kg/minute) with either placebo or no dopamine in women with severe pre-eclampsia and acute renal failure, or who are considered to be at risk of acute renal failure. DATA COLLECTION AND ANALYSIS: The two review authors assessed trial quality and data independently. MAIN RESULTS: Only one randomised placebo controlled trial of six hours' duration, including 40 postpartum women, was found. This study showed a significant increase in urinary output over six hours in women receiving dopamine. It is unclear if this was of any benefit to the women. AUTHORS' CONCLUSIONS: It is unclear whether low-dose dopamine therapy for pre-eclamptic women with oliguria is worthwhile. It should not be used other than in prospective trials.
Authors: Carlos F Cáceres; Florence Koechlin; Pedro Goicochea; Papa-Salif Sow; Kevin R O'Reilly; Kenneth H Mayer; Peter Godfrey-Faussett Journal: J Int AIDS Soc Date: 2015-07-20 Impact factor: 5.396